Home > Drugs A – Z > Infliximab (By injection)

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Infliximab injection is used in adults to treat Crohn disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis. It is used in children to treat Crohn disease and ulcerative colitis. Infliximab injection is a monoclonal antibody that works to enhance and improve the immune system. This medicine is available only with your… Read more
Brand names include
Inflectra, Remicade
Drug classes About this
Gastrointestinal Agent, Immunological Agent

What works? Research summarized

Evidence reviews

Infliximab for rheumatoid arthritis

Infliximab in combination with methotrexate is an effective treatment for rheumatoid arthritis( RA).

Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab: A Review of the Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet]

The availability of biosimilar infliximab (INX) has been postulated to offer cost savings compared to innovator INX, which could lead to patients being switched between products. The purpose of this report is to summarize the comparative clinical and cost effectiveness of switching from innovator to biosimilar INX compared to continued use of innovator INX over a broad range of indications.

A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease

Crohn's disease (CD) is a severe, lifelong disease characterised by inflammation of the gastrointestinal mucosa. The impact on patients and society is high as ill health can be lifelong and can negatively affect patients' quality of life. Costs to the NHS are high, particularly for patients needing hospitalisation. Conventional treatment pathways are complex. More recently, a group of drugs called tumour necrosis factor (TNF) inhibitors (anti-TNF-α agents) have been evaluated for their effectiveness in CD. One of these, infliximab, is currently recommended by the National Institute for Health and Clinical Excellence (NICE; 2002) for patients with severe, active CD where patients are refractory to or intolerant of conventional treatment.

See all (225)

Summaries for consumers

Infliximab for rheumatoid arthritis

Infliximab in combination with methotrexate is an effective treatment for rheumatoid arthritis( RA).

Comparing Targeted Immune Modulators

Targeted immune modulators (also referred to as biologics) form a relatively new class of drugs for diseases with chronic inflammation and an inappropriate immune response. Such diseases include rheumatoid arthritis, psoriasis, and inflammatory bowel diseases.

Vedolizumab (Entyvio) for Crohn’s disease: Overview

Vedolizumab (trade name: Entyvio) has been approved in Germany since May 2014 for the treatment of moderate to severe Crohn’s disease.

See all (38)

PubMed Health Blog...

read all...